International Journal of Hematology

, Volume 97, Issue 4, pp 485–490 | Cite as

Feasibility of cord blood transplantation in chemosensitive adult T-cell leukemia/lymphoma: a retrospective analysis of the Nagasaki Transplantation Network

  • Takuya Fukushima
  • Hidehiro Itonaga
  • Yukiyoshi Moriuchi
  • Shinichiro Yoshida
  • Jun Taguchi
  • Yoshitaka Imaizumi
  • Daisuke Imanishi
  • Hideki Tsushima
  • Yasushi Sawayama
  • Emi Matsuo
  • Tomoko Hata
  • Yasushi Miyazaki
Original Article

Abstract

It has been reported that cord blood transplantation (CBT) for patients with aggressive adult T-cell leukemia/lymphoma (ATL) results in poorer outcomes than transplantation using other stem cell sources. To identify a subset of ATL in which CBT is feasible, we retrospectively analyzed 27 patients treated with CBT at three institutions in Nagasaki Prefecture, Japan. The estimated overall survival (OS) rate at 3 years was 27.4 %. Of 16 patients who received CBT during remission (complete, CR, or partial, PR), the OS rate at 3 years was 50 %, while during refractory periods (non-CR or non-PR), the OS rate was 9.1 %. Reduced intensity conditioning (RIC) was given to 18 patients, and myeloablative conditioning (MAC) was used in nine, with 3-year OS of 50.0 and 0 %, respectively. Of the 19 deaths, nine were due to progressive disease, eight (five MAC and three RIC) to infection, and two to multiple organ failure. These results suggest that CBT provides similar results with those in other transplantation procedures for selected ATL patients, such as those in CR or PR. Further studies are needed to evaluate the use of CBT in aggressive ATL.

Keywords

Cord blood transplantation Adult T-cell leukemia/lymphoma Chemosensitivity 

Notes

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Utsunomiya A, Miyazaki Y, Takatsuka Y, Hanada S, Uozumi K, Yashiki S, et al. Improved outcome of adult T-cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 2001;27:15–20.CrossRefGoogle Scholar
  2. 2.
    Kami M, Hamaki T, Miyakoshi S, Murashige N, Kanda Y, Tanosaki R, et al. Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma. Br J Haematol. 2003;120:304–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Fukushima T, Miyazaki Y, Honda S, Kawano F, Moriuchi Y, Masuda M, et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia. 2005;19:829–34.PubMedCrossRefGoogle Scholar
  4. 4.
    Kato K, Kanda Y, Eto T, Muta T, Gondo H, Taniguchi S, et al. Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program. Biol Blood Marrow Transpl. 2007;13:90–9.CrossRefGoogle Scholar
  5. 5.
    Okamura J, Utsunomiya A, Tanosaki R, Uike N, Sonoda S, Kannagi M, et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood. 2005;105:4143–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Tanosaki R, Uike N, Utsunomiya A, Saburi Y, Masuda M, Tomonaga M, et al. Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome. Biol Blood Marrow Transpl. 2008;14:702–8.CrossRefGoogle Scholar
  7. 7.
    Choi I, Tanosaki R, Uike N, Utsunomiya A, Tomonaga M, Harada M, et al. Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: results of prospective trials. Bone Marrow Transpl. 2011;46:116–8.CrossRefGoogle Scholar
  8. 8.
    Hishizawa M, Kanda J, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010;116:1369–76.PubMedCrossRefGoogle Scholar
  9. 9.
    Kanda J, Hishizawa M, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, et al. Impact of graft-versus-host disease on outcome after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood. 2012;119:2141–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Ishida T, Hishizawa M, Kato K, Tanosaki R, Fukuda T, Taniguchi S, et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia–lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood. 2012;120:1734–41.PubMedCrossRefGoogle Scholar
  11. 11.
    Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia–lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113:375–82.PubMedCrossRefGoogle Scholar
  12. 12.
    Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia–lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25:5458–64.PubMedCrossRefGoogle Scholar
  13. 13.
    Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351:2276–85.PubMedCrossRefGoogle Scholar
  14. 14.
    Laughlin M, Espen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE, et al. Outcome after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351:2265–75.PubMedCrossRefGoogle Scholar
  15. 15.
    Uchiyama T, Human T. T cell leukemia virus type I (HTLV-1) and human diseases. Annu Rev Immunol. 1997;15:15–37.PubMedCrossRefGoogle Scholar
  16. 16.
    Vendonck K, Gonzalez E, Van Dooren S, Vandemme AM, Vanharn G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis. 2007;7:266–81.CrossRefGoogle Scholar
  17. 17.
    Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K, Shimohakamada Y, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood. 2004;104:3813–20.PubMedCrossRefGoogle Scholar
  18. 18.
    Takahashi S, Ooi J, Tomonari A, Konuma T, Tsukada N, Oiwa-Monna M, et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood. 2007;109:1322–30.PubMedCrossRefGoogle Scholar
  19. 19.
    Fukushima T, Horio Y, Matsuo E, Imanishi D, Yamasaki R, Tsushima H, et al. Successful cord blood transplantation for mycosis fungoides. Int J Hematol. 2008;88:596–8.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2013

Authors and Affiliations

  • Takuya Fukushima
    • 1
    • 2
  • Hidehiro Itonaga
    • 1
  • Yukiyoshi Moriuchi
    • 3
  • Shinichiro Yoshida
    • 4
  • Jun Taguchi
    • 1
  • Yoshitaka Imaizumi
    • 1
  • Daisuke Imanishi
    • 1
  • Hideki Tsushima
    • 1
  • Yasushi Sawayama
    • 1
  • Emi Matsuo
    • 4
  • Tomoko Hata
    • 1
  • Yasushi Miyazaki
    • 1
  1. 1.Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease InstituteNagasaki University Graduate School of Biomedical SciencesNagasakiJapan
  2. 2.Laboratory of Hematoimmunology, Department of Clinical Laboratory Sciences, Faculty of MedicineSchool of Health Sciences, University of the RyukyusOkinawaJapan
  3. 3.Sasebo City General HospitalSaseboJapan
  4. 4.National Hospital Organization Nagasaki Medical CenterOhmuraJapan

Personalised recommendations